Journey of remdesivir from the inhibition of hepatitis C virus to the treatment of COVID-19 [0.03%]
从抑制丙型肝炎病毒到治疗新型冠状病毒肺炎瑞德西韦的历程
Tomas Cihlar,Richard L Mackman
Tomas Cihlar
If a planned path reaches a dead-end, one can simply stop. Or one can turn around, walk back to the last intersection and take another path, or one can consider taking few paths in parallel. The last scenario is reflective of the journey of...
Commentary: Development of Therapeutics for Congenital Cytomegalovirus Infection [0.03%]
论著评论：先天性巨细胞病毒感染的治疗药物研发进展
Richard J Whitley
Richard J Whitley
In the mid 1980's, I flew from Birmingham, Alabama to San Francisco, rented a car, and drove to Palo Alto so that I could meet with John Martin at Syntex. John, along with Julian Verheyden, synthesized ganciclovir, which had significant in ...
Madhu C Choudhary,John W Mellors
Madhu C Choudhary
A co-formulated, one pill once a day antiretroviral regimen (single-tablet regimen), containing efavirenz, emtricitabine, and tenofovir disoproxyl fumarate (Atripla), revolutionized the antiretroviral therapy landscape. Single-tablet regime...
Providing access to high-quality, low-cost medicines across low and middle-income countries (LMICs), working with governments and generic manufacturers around the globe - A business case [0.03%]
在发展中国家提供高质量低成本的药品与全球政府和仿制药品生产商合作-一个商业案例分析
Gregg Alton,Clifford Samuel,Anand Reddi
Gregg Alton
Background: Gilead Sciences, under Dr. John Martin's leadership, created its Global Access Program to deliver high-quality, affordable medicines to treat and ultimately eliminate some of the world's most challenging-to-tr...
The best backbone for HIV prevention, treatment, and elimination: Emtricitabine+tenofovir [0.03%]
最佳的艾滋病预防、治疗和清除骨架药物：恩曲他滨+替诺福韦
Raymond F Schinazi,Dharmeshkumar Patel,Maryam Ehteshami
Raymond F Schinazi
The advent of antiretroviral combination therapy has significantly impacted the HIV/AIDS epidemic. No longer a death sentence, HIV infection can be controlled and suppressed using cocktail therapies that contain two or more small molecule d...
The making of the one pill-Developing single tablet regimens for HIV and for HCV [0.03%]
一-pill的诞生——艾滋病和丙肝单片疗法的研发历程
Taiyin Yang,Reza Oliyai,Kenneth M Kent
Taiyin Yang
A concept of "all or nothing" inspired the innovation of a one-pill-once-daily HIV treatment. Atripla® was the one pill that combined efavirenz, emtricitabine, and tenofovir disoproxil fumarate to become the first daily single tablet regim...
Markus Cornberg,Michael P Manns
Markus Cornberg
The development of direct-acting antivirals (DAA) has revolutionized the treatment of chronic hepatitis C, enabling cure of hepatitis C virus (HCV) infection in more than 95% of cases. There are essentially no contraindications, so almost a...
Case study of hepatitis C virus control in Egypt: impact of access program [0.03%]
埃及乙肝病毒控制案例研究：获取方案的影响
Imam Waked
Imam Waked
Background: Although Egypt was the country with the highest prevalence of hepatitis C in the world, the availability of sofosbuvir based therapies enabled Egypt to be the first country to eliminate hepatitis C and cure mo...
Virus reactivation in a non-cirrhotic HBV patient requiring liver transplantation after cessation of nucleoside analogue therapy [0.03%]
乙型肝炎患者停用核苷类似物后需进行肝脏移植的病毒再活化
Han Zhang,Fang Chen,Erick Giang et al.
Han Zhang et al.
Nucleos(t)ide analogues (NAs) are a mainstay of therapy for chronic hepatitis B (CHB) infections and have a profound effect on hepatitis B virus (HBV) suppression. We report a rare case of HBV reactivation in a CHB patient without cirrhosis...
Pharmacokinetics, safety and tolerability of single- and multiple-ascending doses of JNJ-64530440, a novel hepatitis B virus capsid assembly modulator, in healthy volunteers [0.03%]
JNJ-64530440的药代动力学、安全性和耐受性：一种新型乙型肝炎病毒衣壳装配调节剂在健康志愿者中的剂量递增研究
Thomas N Kakuda,Jeysen Z Yogaratnam,Christopher Westland et al.
Thomas N Kakuda et al.
Background: Pharmacokinetics and safety of JNJ-64530440, a hepatitis B virus capsid assembly modulator producing normal empty capsids (CAM-N), in healthy volunteers were evaluated. ...
Clinical Trial
Antiviral therapy. 2021 Jan-Feb;26(1-2):13-24. DOI:10.1177/13596535211044331 2021